Under a new commercialization agreement with Samsung Bioepis, the developer of Epysqli (eculizumab-aagh), Teva Pharmaceuticals will have exclusive marketing rights in the U.S. for the Soliris (eculizumab) biosimilar — an approved treatment for atypical hemolytic uremic syndrome (aHUS). A biosimilar is a biological product that is highly similar to…
Read more
I step out of the shower and face the stranger looking back at me in the mirror. My thin, brittle hair has more gray in it than before, and my scalp is riddled with bald spots. My forehead feels like a blank canvas because my eyebrows and eyelashes are missing.
Becoming educated and informed about aHUS is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnist’s words of wisdom to help you along on your aHUS journey.
There is no cure for aHUS yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
